

RECEIVED
CENTRAL FAX CENTER

FEB 05 2007

REMARKS

In response to the Restriction Requirement issued by the PTO, Applicants hereby elect, without traverse, to prosecute the claims of Group I, e.g., Claims 75-77, drawn to a method for assessing the effectiveness of non-nucleoside reverse transcriptase inhibitor antiretroviral therapy (NNRTI) by evaluating plasma samples for mutations at codon 236 in the HIV reverse transcriptase (RT), classified in class 435, subclasses 5 and 91.2, and class 536, subclasses 27.72 and 24.33. Applicants reserve the right to pursue the unelected subject matter in one or more related divisional, continuation, or continuation, or continuation-in-part applications.

In light of the above remarks, the Applicant respectfully requests that the Examiner consider this application with a view towards allowance. The Examiner is invited to call the undersigned attorney if a telephone call could help resolve any remaining items.

Respectfully submitted,

Date: February 5, 2007

40,895

(Reg. No.)

H. Thomas Anderton, Jr.
Monogram Biosciences, Inc.
345 Oyster Point Blvd.
South San Francisco CA 94080